Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients

Anti-Cancer Drugs

Volumn 9, Issue 7, 1998, Pages 611-619

  Socinski, Mark A ^a   Mudd Jr , Paul N ^a   Radomski, Kristine M ^a   Steagall, Ann ^a   Lawrence, Pam ^a   Bernard, Stephen ^a   Letrent, Stephen P ^a   Gonzalez, Pablo ^a   Brouwer, Kim L R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Continuous infusion; Paclitaxel; Phase I study

Indexed keywords

DEXAMETHASONE; PACLITAXEL; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION TEST; LUNG SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS, PHASE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FILGRASTIM; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; PACLITAXEL; SKIN NEOPLASMS; TIME FACTORS;

EID: 0031716320     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199808000-00006     Document Type: Article

References (24)

1. Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 2352-7.
2. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979; 277: 665-7.
3. Schiff PB, Howitz SB. Taxol stabilizes microtubules in mouse flbroblast cell. Proc Natl Acad Sci USA 1980; 77: 1561-5.
4. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 15: 1004-14.
5. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage in and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-8.
6. Bonomi P, Kim K, Kugler J, Johnson D. Comparison of survival for stage IIIB versus stage IV non-small cell lung cancer (NSCLC) patients treated with etoposide-cisplatin versus Taxol-cisplatin: an Eastern Cooperative Group (ECOG) trial. Proc Am Soc Clin Oncol 1997; 16. 454a.
7. Hainsworth J, Greco A. Paclitaxel administered by 1-hour infusion - preliminary results of a phase I/II trial comparing two schedules. Cancer 1994; 74: 1377-82.
8. Seidman AD, Tierstan A, Hudis C, et al. Phase II trial of paclitaxel by 3 hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13: 2575-81.
9. Chang AY, Kim K, Glick J, et al. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 95: 388-94.
10. Wilson WH, Berg S, Byant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase II trial of 96 hour infusion. J Clin Oncol 1994; 2: 1621-9.
11. Spriggs DR, Tondini C. Taxol administered as a 120 hour infusion. Invest New Drugs 1992; 10: 275-8.
12. Skubitz KM. A phase I study of ambulatory continuous infusion paclitaxel. Anti-Cancer Drugs 1997; 8: 823-8.
13. Zhan A, Kang YK, Regis J, et al. Taxol resistance: in vitro and in vivo studies in breast cancer and lymphoma. Proc Am Ass Cancer Res 1993; 34: 215.
14. Georgiadis MS, Russell E, Johnson BE. Prolonging the exposure of human lung cancer cell lines to paclitaxel improves the cytotoxicity. Proc Am Ass Cancer Res 1994; 35: 341.
15. Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996; 14: 1877-84.
16. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 319: 1414-22.
17. Miller AB, Hoogstraten B, Staquent M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
18. 2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 1993; 33: 48-52.
19. Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994; 48: 794-847.
20. Fetell MR, Grossman SA, Fisher JD, et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. J Clin Oncol 1997; 15: 3121-8.
21. Soulie' P, Trandafir L, Taamma A, et al. Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer. Anti-Cancer Drugs 1997; 8: 763-6.
22. Markman M, Rose P, Kennedy A, et al. A Phase II study of 96 hour paclitaxel (P) as salvage therapy in ovarian carcinoma (OC). Proc Am Soc Clin Oncol 1996; 5: 283.
23. Socinski MA, Steagall A, Gillenwater H. Second Line chemotherapy with 96 hour paclitaxel in refractory non-small cell lung cancer: report of a phase II trial. Cancer Invest 1998; in press.
24. Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus and estramustine phosphate or metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 15: 3156-63.